Comparative Pharmacology
Head-to-head clinical analysis: GENOPTIC versus GENTAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOPTIC versus GENTAK.
GENOPTIC vs GENTAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
None Documented
None Documented
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic